Nivolumab-associated pulmonary and bone sarcoidosis in a patient with melanoma of unknown primary

Rima I. Tulbah, Steven Rowe, Lilja Solnes, Mehrbod S. Javadi

Research output: Contribution to journalArticle


A 57-year-old man with stage IIIB malignant melanoma of unknown primary presented for pretherapy FDG PET/CT that demonstrated metastatic left cervical lymph node with no other site of involvement. Following left neck dissection, nivolumab was initiated. Follow-up FDG PET/CT 3 months after initiation of nivolumab demonstrated extensive radiotracer-avid chest lymphadenopathy and multiple bone lesions. Ultrasound-guided endobronchial biopsy of the mediastinal lymph nodes demonstrated sarcoidosis.

Original languageEnglish (US)
Pages (from-to)E519-E521
JournalClinical nuclear medicine
Issue number9
Publication statusPublished - Sep 1 2019



  • Malignant melanoma
  • Nivolumab
  • Osseous sarcoidosis
  • Pulmonary sarcoidosis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this